Voyager Therapeutics (VYGR) Total Current Liabilities (2014 - 2026)

Voyager Therapeutics has reported Total Current Liabilities for 13 years, with the latest figure at $17.5 million in Q1 2026.

• Quarterly Total Current Liabilities fell 56.6% year-over-year to $17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.5 million (down 56.6% YoY) and the FY2025 annual result came in at $26.5 million, down 46.69% from the prior year.
• Total Current Liabilities fell to $17.5 million in Q1 2026 per VYGR's latest filing, from $26.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $101.7 million in Q1 2022 and troughed at $17.5 million in Q1 2026.
• A 5-year average of $53.3 million and a median of $45.4 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 310.8% in 2022, then sank 80.39% in 2023.
• Over 5 years, Total Current Liabilities stood at $72.6 million in 2022, then dropped by 11.13% to $64.5 million in 2023, then slipped by 22.82% to $49.8 million in 2024, then tumbled by 46.69% to $26.5 million in 2025, then plunged by 34.24% to $17.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $17.5 million, $26.5 million, and $35.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.